Zions Bancorporation National Association UT Increases Stock Holdings in Pfizer Inc. $PFE

Zions Bancorporation National Association UT boosted its stake in Pfizer Inc. (NYSE:PFE) by 25.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 344,625 shares of the biopharmaceutical company’s stock after buying an additional 69,497 shares during the quarter. Zions Bancorporation National Association UT’s holdings in Pfizer were worth $8,354,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Pacer Advisors Inc. lifted its position in shares of Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after purchasing an additional 17,957,928 shares in the last quarter. Amundi increased its stake in Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after buying an additional 15,758,846 shares during the last quarter. Nuveen LLC bought a new position in shares of Pfizer during the 1st quarter worth approximately $389,861,000. Goldman Sachs Group Inc. boosted its stake in shares of Pfizer by 51.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after buying an additional 9,041,990 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after acquiring an additional 4,629,976 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. Citigroup increased their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $28.18.

Pfizer Trading Down 1.6%

Shares of Pfizer stock opened at $24.45 on Friday. The stock has a market capitalization of $138.99 billion, a P/E ratio of 13.00, a P/E/G ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock’s 50-day simple moving average is $24.74 and its 200 day simple moving average is $24.37.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.